Medical Condition News

RSS

VBL Therapeutics announces upcoming presentations at premier dermatology and cancer research meetings

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immuno-inflammatory diseases and cancer, today announced the upcoming presentations of clinical data from the company's two lead programs, VB-201 and VB-111, at premier dermatology and cancer research medical meetings this spring.

13 Apr 2010

Over 17,000 scientists convene at AACR 101st Annual Meeting 2010

Scientific breakthroughs in molecular targeting, translational cancer research and cancer prevention will take center stage when more than 17,000 scientists from around the world gather at the Walter E. Washington Convention Center, April 17-21, for the AACR 101st Annual Meeting 2010.

13 Apr 2010

Delcath's Phase III PHP-mel trial data accepted for presentation at ASCO's 2010 Annual Meeting

Delcath Systems, Inc., a medical technology company testing its proprietary treatment system for primary and metastatic cancers to the liver, announced today that the American Society of Clinical Oncology (ASCO) has accepted an abstract for oral presentation of Delcath's Phase III Trial Data comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to the best alternative care for patients with hepatic metastases from ocular or cutaneous melanoma for ASCO's 2010 Annual Meeting, to be held June 4-8, 2010 at McCormick Place in Chicago.

13 Apr 2010

New driving guideline for people with Alzheimer's disease

The American Academy of Neurology has issued a new guideline to help determine when people with Alzheimer's disease or another type of dementia should stop driving. The guideline is published in the April 12, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology, and was presented at the American Academy of Neurology's Annual Meeting in Toronto.

13 Apr 2010

High level of microRNAs found in patients with high-risk multiple myeloma

Multiple myeloma researchers at the University of Arkansas for Medical Sciences (UAMS) recently discovered that widespread activity of a specific class of genes can identify aggressive, or high-risk, cases of the disease.

13 Apr 2010

Investment report on Rexahn Pharmaceuticals

StockPreacher.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

13 Apr 2010

'Mindfulness' for reducing aggressive behaviour in people with developmental disabilities

A very ancient and effective practice - mindfulness - is being given a new and surprising application. For the first time ever, mindfulness is being used to reduce the likelihood of aggressive behaviour in people with developmental disabilities as well as mental health problems.

13 Apr 2010

Circadian cell division gets disrupted due to artificial light at night

Just one "pulse" of artificial light at night disrupts circadian cell division, reveals a new study carried out by Dr. Rachel Ben-Shlomo of the University of Haifa-Oranim Department of Environmental and Evolutionary Biology along with Prof. Charalambos P. Kyriacou of the University of Leicester. "Damage to cell division is characteristic of cancer, and it is therefore important to understand the causes of this damage," notes Dr. Ben-Shlomo. The study has been published in the journal Cancer Genetics and Cytogenetics.

13 Apr 2010

Dalhousie University interdisciplinary cooperation leads to innovation of Femoral Fracture Reduction device

It's late at night when most of the city is sleeping and the hospital is eerily quiet. But in the operating room, a tired but undeterred surgeon is struggling through a femoral fracture reduction on a young patient. The surgery, which is usually a meticulous and straightforward procedure, is not going smoothly. After wrestling with the fracture, he has no choice but to take a more invasive approach. He cuts open the femur and reduces the fracture—if not, displaced fat and marrow could cause a fat embolism in the lungs.

13 Apr 2010

Touching story of young man fighting Alzheimer's disease

In her new unwavering memoir, Jim's Journey: The Story of a Young Man with Early On-set Alzheimer's (published by Trafford Publishing), debut author Gretchen L Dausey reveals the touching story of her husband's battle against Alzheimer's disease and her unwavering support despite the inevitable degeneration of his mind and body.

13 Apr 2010

BioTrends Research Group, NKF publish Special Report on patients with CKD

BioTrends Research Group, Inc. and the National Kidney Foundation announce the publication of a Special Report: Patient Perspectives in Dialysis and Chronic Kidney Disease. This important new syndicated study provides insights into patients with kidney disease, from the patients themselves. Over 1,100 patients in the U.S. -- both those on dialysis and those with mid-late stage chronic kidney disease -- completed a survey about living with CKD.

13 Apr 2010

'Forgotten' cells in brain cancer

Glioblastoma is a guileful enemy. While most of the brain tumor can often be removed surgically, in virtually every case the tumor reappears. One reason for this is that sporadic, infiltrative tumor cells will remain in the brain even after most careful surgery. Researchers at the University of Bonn have now subjected these 'forgotten' cells to closer scrutiny for the first time.

13 Apr 2010

American Lung Association's report examines lung cancer among African Americans

The American Lung Association today released its report, Too Many Cases, Too Many Deaths: Lung Cancer in African Americans, a compilation of research examining lung cancer among African Americans and the need to eliminate this and other health disparities.

13 Apr 2010

XOMA expands anti-inflammatory antibody intellectual property portfolio

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Patent and Trademark Office has issued two new patents that significantly expand the company's intellectual property portfolio relating to its anti-inflammatory antibody, XOMA 052, that targets interleukin-1 beta (IL-1 beta).

13 Apr 2010

TD2, Horizon Discovery announce strategic alliance to advance personalized medicine

A strategic alliance announced today between TGen Drug Development (TD2) and Horizon Discovery Limited will significant advance personalized medicine.

13 Apr 2010

New article focuses on the role of registered dietitians in patient management

More than one third of Americans are considered obese and approximately 15 million (5%) Americans now have a body mass index greater than 40. The April issue of the Journal of the American Dietetic Association focuses on the ever-increasing use of bariatric surgery to control the excess morbidity and mortality associated with extreme obesity and the important role that registered dietitians play in the management of patients who have undergone the procedure.

13 Apr 2010

First direct recording of mirror neurons in the brain

Mirror neurons, many say, are what make us human. They are the cells in the brain that fire not only when we perform a particular action but also when we watch someone else perform that same action.

13 Apr 2010

Tips for protection against sun damage

It's never too early to start protecting yourself against sun damage, and if you are a teenage girl this message is especially important.

13 Apr 2010

Study identifies pathway linked to rheumatoid arthritis

Investigators from Hospital for Special Surgery have identified a pathway involved in turning off inflammation that does not work properly in people with inflammatory arthritis. The finding, reported in the April 23 issue of the journal Immunity, could lead to the development of new therapeutic approaches to treating arthritis in the future.

13 Apr 2010

Copaxone achieves one million patient years of experience in treatment of RRMS

Teva Pharmaceutical Industries, Ltd. announced today that Copaxone® (glatiramer acetate injection), has now achieved one million patient years of experience in the treatment of relapsing-remitting multiple sclerosis (RRMS). This analysis is based on internal data submitted annually to the U.S. Food and Drug Administration (FDA).

13 Apr 2010